Graham Holdings Co Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $5.1B+5.8% YoYTTM through 30 Jun 2026
Net Income $541.9M-25.2% YoYTTM through 30 Jun 2026
Free Cash Flow $267.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 29.9% |
| EBITDA Margin | 7.0% |
| Operating Margin | 4.8% |
| Net Margin | 10.7% |
Returns
6.1%ROE
3.5%ROA
9.8%ROIC
Balance Sheet Health
Debt / Equity0.18x
Current Ratio1.86x
Net Debt$745.1M
Cash & Equivalents$156.8M
Quality Metrics
Altman Z-Score3.24
Piotroski F-Score5 / 9
FCF Margin5.3%
Rule of 408.0
Multi-Year Trend
RevenueFY2025: $4.9B
Diluted EPS$123.70TTMFY2025: $66.47
Dividend
$5.64Per share, FY20260.49%Yield-1.4%5-yr growth
Capital Allocation
Capex Intensity1.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Automotive | $1.1B | -5.6% | View detailsOperating results for 2025 declined due to lower overall sales and gross margins on new and used vehicles. |
| Kaplan International | $1.1B | +0.6% | View detailsReported revenue and operating income growth for 2025 due largely to increases at UK Professional and Singapore. |
| CSI Pharmacy Holding Company, LLC (CSI) | $466M | View detailsContinues to scale its footprint and offerings in the in-home infusion market. | |
| Manufacturing | $436M | +10.1% | View detailsBenefiting from recovery and onshoring trends following supply-chain disruptions. |
| Television Broadcasting | $425M | -20.7% | View detailsRevenues and operating results declined in 2025 due to cyclical advertising trends. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.